Roivant Sciences Ltd. (ROIV) Financial Ratios
6 years of historical data (2019–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 0.60
30Y Low0.6·High0.6
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
3.95
↑+84% vs avg
5yr avg: 2.15
30Y Low1.4·High3.3
ROE
↑
-3.0%
↓+47% vs avg
5yr avg: -5.6%
30Y Low-55%·High108%
Debt/EBITDA
N/A
—
5yr avg: 0.11
30Y Low0.1·High0.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ROIV Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Roivant Sciences Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $20.5B | $7.3B | $8.8B | $5.3B | $3.3B | $6.7B | — |
| Enterprise Value | $17.9B | $4.7B | $2.7B | $4.1B | $1.5B | $4.8B | — |
| P/E Ratio → | -117.83 | — | 2.02 | — | — | — | — |
| P/S Ratio | 706.10 | 251.93 | 267.76 | 85.84 | 59.84 | 281.46 | — |
| P/B Ratio | 3.95 | 1.41 | 1.36 | 3.27 | 1.60 | 3.10 | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ROIV EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 161.91 | 83.25 | 66.33 | 27.71 | 202.12 | — |
| EV / EBITDA | — | — | 0.60 | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
ROIV Profitability
Margins and return-on-capital ratios measuring operating efficiency
Roivant Sciences Ltd. earns an operating margin of -3453.3%. Operating margins have compressed from -1917.9% to -3453.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -3.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 96.9% | 96.9% | 95.1% | 78.6% | 83.8% | 91.4% | 98.3% |
| Operating Margin | -3453.3% | -3453.3% | 13746.9% | -1917.9% | -2444.8% | -4500.5% | -786.6% |
| Net Profit Margin | -592.0% | -592.0% | 13294.2% | -1646.6% | -1528.9% | -3400.9% | 1773.6% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -3.0% | -3.0% | 108.0% | -55.0% | -40.0% | -37.9% | 56.9% |
| ROA | -2.7% | -2.7% | 90.5% | -40.6% | -32.0% | -31.3% | 48.5% |
| ROIC | -50.4% | -50.4% | 817.9% | -252.9% | -362.6% | -424.6% | -383.6% |
| ROCE | -16.4% | -16.4% | 99.1% | -52.0% | -55.5% | -44.1% | -22.3% |
ROIV Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2.7B exceeds total debt of $100M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.08 | 0.30 | 0.14 | 0.11 | 0.09 |
| Debt / EBITDA | — | — | 0.11 | — | — | — | — |
| Net Debt / Equity | — | -0.50 | -0.94 | -0.74 | -0.86 | -0.87 | -0.95 |
| Net Debt / EBITDA | — | — | -1.34 | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | 129.31 | -42.02 | -191.97 | -381.24 | -69.30 |
Net cash position: cash ($2.7B) exceeds total debt ($100M)
ROIV Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Roivant Sciences Ltd.'s current ratio of 33.47x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 6.60x to 33.47x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 33.47 | 33.47 | 25.24 | 6.60 | 11.64 | 9.99 | 24.09 |
| Quick Ratio | 33.47 | 33.47 | 25.10 | 6.59 | 11.64 | 9.99 | 24.09 |
| Cash Ratio | 32.71 | 32.71 | 24.52 | 6.17 | 11.18 | 9.74 | 23.72 |
| Asset Turnover | — | 0.01 | 0.00 | 0.03 | 0.02 | 0.01 | 0.03 |
| Inventory Turnover | 0.05 | — | 0.05 | 4.75 | — | — | — |
| Days Sales Outstanding | — | — | 924.00 | 224.22 | 44.44 | 212.17 | 82.39 |
ROIV Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Roivant Sciences Ltd. returns 6.3% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 0.1% | — | — | — | — |
| Payout Ratio | — | — | 0.1% | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 49.6% | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 6.3% | 17.7% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 6.3% | 17.7% | 0.1% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $725M | $831M | $713M | $670M | $685M | $685M |
Peer Comparison
Compare ROIV with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ROIVYou | $21B | -117.8 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
 BHVN | $1B | -1.4 | — | — | — | — | -310.8% | -242.1% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 BMY | $115B | 16.3 | 9.2 | 8.9 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 VTRS | $20B | -5.8 | 248.5 | 10.5 | 35.1% | -18.6% | -21.1% | -6.6% | 108.7 |
 JAZZ | $14B | -38.9 | 23.8 | 11.0 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
Full ROIV Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ROIV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ROIV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ROIV vs BHVN
Side-by-side business, growth, and profitability comparison vs Biohaven Ltd..
Start ComparisonROIV — Frequently Asked Questions
Quick answers to the most common questions about buying ROIV stock.
What is Roivant Sciences Ltd.'s P/E ratio?
Roivant Sciences Ltd.'s current P/E ratio is -117.8x. The historical average is 2.0x.
What is Roivant Sciences Ltd.'s ROE?
Roivant Sciences Ltd.'s return on equity (ROE) is -3.0%. The historical average is 4.8%.
Is ROIV stock overvalued?
Based on historical data, Roivant Sciences Ltd. is trading at a P/E of -117.8x. Compare with industry peers and growth rates for a complete picture.
What are Roivant Sciences Ltd.'s profit margins?
Roivant Sciences Ltd. has 96.9% gross margin and -3453.3% operating margin.